Hydroxylamine derivatives
View Patent ↗This invention is related to hydroxylamino derivatives of the general formula (I) wherein n is 0, 1 or 2; R 1 and R 2 , independently of each other, are H, OH or OCH 3 ; R 3 is H or CH 3 ; R 4 is H, C 1 -C 3 straight or branched alkyl or, together with R 3 , forms a five to seven-membered carbocyclic ring; and R 5 and R 6 , independently of each other, are H or C 1 -C 5 straight or branched alkyl and the pharmaceutically acceptable salts or prodrug thereof, for the preparation of medicaments useful for the prevention, treatment and diagnosis of CNS degenerative disorders related to protein misfolding and/or misaggregation. The invention also relates to novel compounds included in formula (I), to a method for preparing said compounds and to pharmaceutical compositions containing them.
1. A compound of the formula:
and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are chosen such that the compound is selected from the group consisting of:
N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-hydroxylamine;
N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-ethyl-hydroxylamine;
N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-ethyl-hydroxylamine;
N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-butyl-O-ethyl-hydroxylamine;
N-(5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-butyl-O-propyl-hydroxylamine;
N-(5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
N-(5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-ethyl-hydroxylamine;
N-(5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
N-(1-methyl-2-(3-hydroxy-phenyl)-ethyl)-hydroxylamine;
N-(1-methyl-2-(3-hydroxy-phenyl)-ethyl)-N-methyl-hydroxylamine;
N-(1-methyl-2-(3-hydroxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
N-(1-methyl-2-(3,4-dihydroxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
N-(1-methyl-2-(3-methoxy-phenyl)-ethyl)-N-methyl-hydroxylamine;
N-(1-methyl-2-(3-methoxy-phenyl)-ethyl)-N-propyl-hydroxylamine; hydroxylamine;
N-(1-methyl-2-(3,4-dimethoxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
N-(5-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
N-(5-methoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
N-(5,6-dihydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
N-(5,6-dimethoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
N-(5-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
N-(5-methoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
N-(5,6-dihydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propryl-O-ethyl-hydroxylamine;
N-(5,6-dimethoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-hydroxylamine;
N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-O-ethyl-hydroxylamine;
N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-methyl-hydroxylamine;
N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-propyl-hydroxylamine;
N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-propyl-O-ethyl-hydroxylamine;
N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-hydroxylamine;
N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-O-ethyl-hydroxylamine;
N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-methyl-hydroxylamine;
N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-propyl-hydroxylamine;
N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-propyl-O-ethyl-hydroxylamine; and
the pharmaceutically acceptable salts thereof.
2. A pharmaceutical composition comprising one or more compounds according to claim 1 in a mixture with suitable excipients and/or carriers.
3. A pharmaceutical composition comprising one or more compounds according to claim 1 and a compound for the treatment of central and peripheral nervous system disorders involving protein misfolding and/or misaggregation of beta-amyloid peptide, alpha-synuclein, prion protein and huntingtin selected from Alzheimer's Disease, Lewy body disease, Parkinson's Disease, spongiform encephalopathies, Huntington's Disease and systemic AA amyloidosis, in admixture with suitable excipients and/or carriers.